Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability (2010 - 2023)

Anika Therapeutics (ANIK) has reported Non-Current Deferred Tax Liability for 14 consecutive years, with $2.0 million the latest figure, recorded in Q3 2023.

• In Q3 2023, Non-Current Deferred Tax Liability fell 71.25% year-over-year to $2.0 million; the TTM figure through Sep 2023 stood at $2.0 million (down 71.25% YoY), while the FY2022 annual figure was $6.4 million, down 36.63% from the prior year.
• Non-Current Deferred Tax Liability fell to $2.0 million in Q3 2023 per ANIK's latest filing, from $3.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $16.0 million in Q1 2020 and bottomed at $2.0 million in Q3 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $8.4 million across 5 years, with a median of $8.2 million in 2022.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability jumped 373.14% — and 2023, when it sank 71.25%.
• Anika Therapeutics' Non-Current Deferred Tax Liability stood at $4.3 million in 2019, then jumped by 174.65% to $11.9 million in 2020, then decreased by 14.61% to $10.2 million in 2021, then tumbled by 36.63% to $6.4 million in 2022, then tumbled by 69.62% to $2.0 million in 2023.
• Business Quant data shows ANIK's Non-Current Deferred Tax Liability at $2.0 million in Q3 2023, $3.2 million in Q2 2023, and $4.1 million in Q1 2023.